Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 101 to 110 of 220 total matches.

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
, and generics; Syndros) and nabilone (Cesamet) are synthetic forms of THC indicated for chemotherapy-induced ...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 |  Show IntroductionHide Introduction

Darbepoetin (Aranesp) - A long-acting Erythropoietin

   
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001  (Issue 1120)
− A double-blind study in 320 patients with lung cancer receiving chemotherapy found that darbepoetin SC ...
Darbepoetin alfa (Aranesp) has been approved by the FDA for treatment of anemia caused by chronic renal disease and will probably also be approved for use in patients with cancer..
Med Lett Drugs Ther. 2001 Dec 10;43(1120):109-10 |  Show IntroductionHide Introduction

Trimetrexate

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989  (Issue 784)
responders (B Akil et al, 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles ...
Trimetrexate glucuronate (Parke-Davis), an investigational drug, is now available in the USA from the National Institute of Allergy and Infectious Diseases (NIAID) for treatment of selected AIDS patients with Pneumocystis carinii pneumonia (PCP). For this indication, trimetrexate is always used concurrently with leucovorin (Wellcovorin; and others).
Med Lett Drugs Ther. 1989 Jan 27;31(784):5-6 |  Show IntroductionHide Introduction

Ifosfamide and Mesna

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989  (Issue 804)
) for concurrent use with other drugs in third-line chemotherapy of metastatic germ-cell testicular cancer. Given ...
Ifosfamide (Ifex - Mead Johnson), a synthetic analog of cyclophosphamide (Cytoxan; and others), has been approved by the US Food and Drug Administration (FDA) for concurrent use with other drugs in third-line chemotherapy of metastatic germ-cell testicular cancer. Given concomitantly, a synthetic sulfhydryl compound known as mesna (Mesnex - Asta) acts in the urine to detoxify metabolites of ifosfamide that cause hemorrhagic cystitis (H Burkert, Cancer Treat Rev, 10 suppl A:175, 1983). Ifosfamide and mesna are available together from Bristol-Myers Oncology Division.
Med Lett Drugs Ther. 1989 Nov 3;31(804):98-9 |  Show IntroductionHide Introduction

BCG For Bladder Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
cystectomy for complete eradication; a minority respond to intravesical chemotherapy, but usually ...
BCG Live (TheraCys - Connaught) and BCG Vaccine U.S.P. (TiceBCG - Organon), freeze-dried suspensions of an attenuated strain of Mycobacterium bovis, were recently approved by the US Food and Drug Administration for intravesical treatment of primary or relapsed carcinoma in situ of the bladder, with or without associated papillary tumors. BCG is not recommended for treatment of papillary tumors occurring alone.
Med Lett Drugs Ther. 1991 Apr 5;33(841):29-30 |  Show IntroductionHide Introduction

Altretamine For Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991  (Issue 850)
, 10:827, 1990). CLINICAL TRIALS — As A Single Agent − Standard first-line chemotherapy for ovarian ...
Altretamine (Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a single agent for palliative oral treatment of persistent or recurrent ovarian cancer.
Med Lett Drugs Ther. 1991 Aug 9;33(850):76-7 |  Show IntroductionHide Introduction

Enzalutamide (Xtandi) for Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013  (Issue 1411)
, and their tumors eventually become resistant to hormone treatment. Docetaxel-based chemotherapy, abiraterone ...
The FDA has approved enzalutamide (en za loo’ ta mide; Xtandi – Astellas/Medivation) for oral treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel (Taxotere, and generics). It is the second oral drug approved for this indication; abiraterone acetate (Zytiga), which is also approved for first-line use, was the first. Cabazitaxel (Jevtana), which is given parenterally, has a similar indication.
Med Lett Drugs Ther. 2013 Mar 4;55(1411):20 |  Show IntroductionHide Introduction

Ziv-Aflibercept (Zaltrap) for Metastatic Colorectal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013  (Issue 1415)
to chemotherapy, is a standard firstand second-line therapy.2,3 these results compare to those achieved ...
Ziv-aflibercept (Zaltrap – Sanofi/Regeneron), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA for use in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for treatment of metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. It is the same drug as aflibercept, which was approved last year as an intravitreal injection (Eylea) for treatment of neovascular (wet) agerelated macular degeneration (AMD). Ziv-aflibercept is the second VEGF inhibitor approved for treatment...
Med Lett Drugs Ther. 2013 Apr 29;55(1415):36 |  Show IntroductionHide Introduction

Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017  (Issue 1527)
and/or chemotherapy, is the treatment of choice for localized soft-tissue sarcoma. Doxorubicin with or without ...
Olaratumab (Lartruvo – Lilly), a platelet-derived growth factor receptor alpha (PDGFR-α) blocking monoclonal antibody, has received accelerated approval from the FDA for use in combination with the anthracycline doxorubicin for first-line treatment of adults with soft-tissue sarcoma histologic subtypes considered susceptible to anthracyclines. Approval is limited to locally advanced or metastatic soft-tissue sarcomas that are not amenable to curative radiotherapy or surgery, and is contingent on verification of clinical benefit in a confirmatory phase 3 trial.
Med Lett Drugs Ther. 2017 Aug 14;59(1527):e138-9 |  Show IntroductionHide Introduction

Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
resection and platinum-based chemotherapy in adults with stage II to IIIA NSCLC whose tumors express PD-L1 ...
Atezolizumab (Tecentriq – Genentech), an immune checkpoint inhibitor, has been approved by the FDA for treatment of unresectable or metastatic alveolar soft part sarcoma (ASPS) in patients ≥2 years old. It was previously approved for treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular cancer, and melanoma (see Table 1). Atezolizumab is the first drug to be approved in the US for treatment of ASPS. ASPS is a rare disorder that affects mostly adolescents and young adults; <1% of soft tissue sarcomas are ASPS.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e56-7   doi:10.58347/tml.2023.1673d |  Show IntroductionHide Introduction